SI2605764T1 - Sestavki za zdravljenje raka - Google Patents

Sestavki za zdravljenje raka

Info

Publication number: SI2605764T1
Authority: SI; Slovenia
Prior art keywords: cancer; compositions; treatment
Prior art date: 2010-08-17

Application number

SI201130486T

Other languages

English (en)

Inventor

Kapil Dhingra

Brian Higgins

Kenneth Kolinsky

Richard J. Lee

Brian Lestini

Kathryn E. Packman

Fei Su

Original Assignee

F. Hoffmann-La Roche Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-08-17

Filing date

2011-08-16

Publication date

2015-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44532840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2605764(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-08-16 Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag

2015-06-30 Publication of SI2605764T1 publication Critical patent/SI2605764T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Mycology (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SI201130486T 2010-08-17 2011-08-16 Sestavki za zdravljenje raka SI2605764T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US37429610P	2010-08-17	2010-08-17
EP11749393.2A EP2605764B1 (en)	2010-08-17	2011-08-16	Compositions for the treatment of cancer
PCT/EP2011/064050 WO2012022724A1 (en)	2010-08-17	2011-08-16	Combination anti - cancer therapy

Publications (1)

Publication Number	Publication Date
SI2605764T1 true SI2605764T1 (sl)	2015-06-30

Family

ID=44532840

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201130486T SI2605764T1 (sl)	2010-08-17	2011-08-16	Sestavki za zdravljenje raka

Country Status (26)

Country	Link
US (1)	US8709419B2 (sl)
EP (1)	EP2605764B1 (sl)
JP (1)	JP5758003B2 (sl)
KR (1)	KR101475167B1 (sl)
CN (1)	CN103153292B (sl)
AR (1)	AR082691A1 (sl)
AU (1)	AU2011290818B2 (sl)
BR (1)	BR112013003530A2 (sl)
CA (1)	CA2807222A1 (sl)
DK (1)	DK2605764T3 (sl)
ES (1)	ES2535000T3 (sl)
HR (1)	HRP20150648T1 (sl)
HU (1)	HUE025187T2 (sl)
IL (1)	IL224395A (sl)
MX (1)	MX349878B (sl)
MY (1)	MY161288A (sl)
NZ (1)	NZ606251A (sl)
PL (1)	PL2605764T3 (sl)
PT (1)	PT2605764E (sl)
RS (1)	RS53959B1 (sl)
RU (1)	RU2607596C2 (sl)
SG (1)	SG188207A1 (sl)
SI (1)	SI2605764T1 (sl)
TW (1)	TWI530287B (sl)
WO (1)	WO2012022724A1 (sl)
ZA (1)	ZA201300967B (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8709419B2 (en)	2010-08-17	2014-04-29	Hoffmann-La Roche, Inc.	Combination therapy
US9295669B2 (en) *	2010-12-14	2016-03-29	Hoffman La-Roche Inc.	Combination therapy for proliferative disorders
EA028821B9 (ru)	2011-02-07	2018-10-31	Плексксикон, Инк.	Соединения и способы для модуляции киназ, а также показания к их применению
US9216170B2 (en)	2012-03-19	2015-12-22	Hoffmann-La Roche Inc.	Combination therapy for proliferative disorders
KR20240146112A (ko)	2012-08-17	2024-10-07	에프. 호프만-라 로슈 아게	코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
JP6855243B2 (ja)	2014-01-24	2021-04-07	エイアイ・セラピューティクス・インコーポレーテッド	癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
US20170027940A1 (en) *	2014-04-10	2017-02-02	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
AU2015342869A1 (en) *	2014-11-07	2017-06-15	AI Therapeutics, Inc.	Apilimod for use in the treatment of renal cancer
US11040027B2 (en)	2017-01-17	2021-06-22	Heparegenix Gmbh	Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018218633A1 (en)	2017-06-02	2018-12-06	Beijing Percans Oncology Co. Ltd.	Combination therapies for treating cancers
WO2019195959A1 (en) *	2018-04-08	2019-10-17	Cothera Biosciences, Inc.	Combination therapy for cancers with braf mutation

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5516807A (en) *	1994-10-25	1996-05-14	Warner-Lambert Company	Method for treating vascular proliferative disorders following balloon angioplasty
AU2001236529A1 (en)	2000-01-26	2001-08-07	Schering Corporation	Combination therapy for cancer
US6545010B2 (en)	2000-03-17	2003-04-08	Aventis Pharma S.A.	Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
JP4679028B2 (ja)	2000-05-15	2011-04-27	セルジーンコーポレイション	結腸直腸癌を治療するための組成物および方法
KR20030063360A (ko)	2000-10-13	2003-07-28	비온 퍼마슈티컬즈 인코포레이티드	에이피/에이엠피 유도 전구약물 형태
GB0123400D0 (en)	2001-09-28	2001-11-21	Novartis Ag	Organic compounds
CA2383259A1 (en)	2002-04-23	2003-10-23	Celator Technologies Inc.	Synergistic compositions
US20080193445A1 (en)	2002-01-18	2008-08-14	Liliane Goetsch	Novel anti-IGF-IR antibodies and uses thereof
WO2003086467A1 (en) *	2002-04-08	2003-10-23	Smithkline Beecham Corporation	Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
US8007826B2 (en)	2003-12-11	2011-08-30	Acorda Therapeutics, Inc.	Sustained release aminopyridine composition
PL1696920T3 (pl)	2003-12-19	2015-03-31	Plexxikon Inc	Związki i sposoby opracowywania modulatorów Ret
US20070281041A1 (en)	2004-03-02	2007-12-06	Introgen Therapeutics, Inc.	Compositions and Methods Involving MDA-7 for the Treatment of Cancer
TW200533339A (en)	2004-03-16	2005-10-16	Bristol Myers Squibb Co	Therapeutic synergy of anti-cancer compounds
NZ551355A (en)	2004-06-03	2009-09-25	Hoffmann La Roche	Treatment of cancer with irinotecan (CPT-11) and erlotinib
KR100851271B1 (ko) *	2004-06-03	2008-08-08	에프. 호프만-라 로슈 아게	이리노테칸 （ｃｐｔ-１１） 및 ｅｇｆｒ-억제제를 이용한치료
CN101155932A (zh)	2005-04-14	2008-04-02	默克专利有限公司	基于在肿瘤组织中增加的egfr基因拷贝数的抗egfr抗体治疗
US20070059310A1 (en)	2005-05-03	2007-03-15	Karel Steven J	Therapeutic combination compositions and methods of using same
US20060257400A1 (en)	2005-05-13	2006-11-16	Bristol-Myers Squibb Company	Combination therapy
US7863288B2 (en)	2005-06-22	2011-01-04	Plexxikon, Inc.	Compounds and methods for kinase modulation, and indications therefor
BRPI0619236A2 (pt)	2005-12-01	2011-09-20	Hoffmann La Roche	derivados de 2,4,5-trifenil imidazolina, composição farmacêutica que os compreende, uso e processo para a sìntese dos mesmos
WO2007128557A1 (en)	2006-05-03	2007-11-15	Bayer Schering Pharma Aktiengesellschaft	Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
MX2009002936A (es) *	2006-09-19	2009-04-01	Novartis Ag	Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf.
PE20121126A1 (es) *	2006-12-21	2012-08-24	Plexxikon Inc	Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
EP2133095A4 (en)	2007-03-05	2012-09-26	Kyowa Hakko Kirin Co Ltd	PHARMACEUTICAL COMPOSITION
EP2173912A4 (en)	2007-08-01	2013-03-20	Idera Pharmaceuticals Inc	NEW SYNTHETIC AGONISTS OF TLR9
EP2244714A4 (en) *	2008-02-08	2012-06-06	Poniard Pharmaceuticals Inc	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
US8354444B2 (en)	2008-09-18	2013-01-15	Hoffmann-La Roche Inc.	Substituted pyrrolidine-2-carboxamides
EP2414356B1 (en)	2009-04-03	2015-09-02	F.Hoffmann-La Roche Ag	Propane-i-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof
US20120035347A1 (en)	2009-04-14	2012-02-09	Schering Corporation	Interferon-alfa sensitivity biomarkers
JP5469744B2 (ja)	2009-05-21	2014-04-16	メルク・シャープ・アンド・ドーム・コーポレーション	インターフェロンアルファ応答に関連する遺伝子マーカー
JP2013502236A (ja)	2009-08-24	2013-01-24	ジェネンテック，インコーポレイテッド	Ｋｒａｓ変異及びｒｔｋ発現レベルを検出することによるｂ−ｒａｆ阻害剤治療に対する細胞の感受性の決定
US20120045433A1 (en)	2010-08-17	2012-02-23	Kapil Dhingra	Combination therapy
US8709419B2 (en)	2010-08-17	2014-04-29	Hoffmann-La Roche, Inc.	Combination therapy
US9295669B2 (en)	2010-12-14	2016-03-29	Hoffman La-Roche Inc.	Combination therapy for proliferative disorders
US9216170B2 (en)	2012-03-19	2015-12-22	Hoffmann-La Roche Inc.	Combination therapy for proliferative disorders

2011
- 2011-08-10 US US13/206,557 patent/US8709419B2/en active Active
- 2011-08-15 TW TW100129120A patent/TWI530287B/zh not_active IP Right Cessation
- 2011-08-15 AR ARP110102961A patent/AR082691A1/es unknown
- 2011-08-16 ES ES11749393.2T patent/ES2535000T3/es active Active
- 2011-08-16 MX MX2013001518A patent/MX349878B/es active IP Right Grant
- 2011-08-16 PT PT117493932T patent/PT2605764E/pt unknown
- 2011-08-16 DK DK11749393.2T patent/DK2605764T3/en active
- 2011-08-16 EP EP11749393.2A patent/EP2605764B1/en active Active
- 2011-08-16 WO PCT/EP2011/064050 patent/WO2012022724A1/en active Application Filing
- 2011-08-16 JP JP2013524438A patent/JP5758003B2/ja active Active
- 2011-08-16 PL PL11749393T patent/PL2605764T3/pl unknown
- 2011-08-16 AU AU2011290818A patent/AU2011290818B2/en not_active Ceased
- 2011-08-16 SG SG2013010640A patent/SG188207A1/en unknown
- 2011-08-16 HU HUE11749393A patent/HUE025187T2/en unknown
- 2011-08-16 RS RS20150260A patent/RS53959B1/en unknown
- 2011-08-16 KR KR1020137006567A patent/KR101475167B1/ko active IP Right Grant
- 2011-08-16 SI SI201130486T patent/SI2605764T1/sl unknown
- 2011-08-16 NZ NZ606251A patent/NZ606251A/en not_active IP Right Cessation
- 2011-08-16 CA CA2807222A patent/CA2807222A1/en not_active Abandoned
- 2011-08-16 RU RU2013110124A patent/RU2607596C2/ru not_active IP Right Cessation
- 2011-08-16 BR BR112013003530A patent/BR112013003530A2/pt not_active Application Discontinuation
- 2011-08-16 MY MYPI2013700258A patent/MY161288A/en unknown
- 2011-08-16 CN CN201180050102.9A patent/CN103153292B/zh active Active
2013
- 2013-01-24 IL IL224395A patent/IL224395A/en active IP Right Grant
- 2013-02-05 ZA ZA2013/00967A patent/ZA201300967B/en unknown
2015
- 2015-06-16 HR HRP20150648TT patent/HRP20150648T1/hr unknown

Also Published As

Publication number	Publication date
JP5758003B2 (ja)	2015-08-05
TWI530287B (zh)	2016-04-21
MY161288A (en)	2017-04-14
PT2605764E (pt)	2015-06-02
US20120045434A1 (en)	2012-02-23
RU2013110124A (ru)	2014-09-27
EP2605764B1 (en)	2015-03-18
PL2605764T3 (pl)	2015-08-31
CN103153292B (zh)	2016-06-29
EP2605764A1 (en)	2013-06-26
IL224395A (en)	2017-09-28
CA2807222A1 (en)	2012-02-23
AU2011290818A1 (en)	2013-02-07
WO2012022724A1 (en)	2012-02-23
NZ606251A (en)	2015-02-27
MX2013001518A (es)	2013-02-27
RU2607596C2 (ru)	2017-01-10
DK2605764T3 (en)	2015-04-07
HRP20150648T1 (hr)	2015-07-31
HUE025187T2 (en)	2016-07-28
CN103153292A (zh)	2013-06-12
TW201212915A (en)	2012-04-01
MX349878B (es)	2017-08-16
BR112013003530A2 (pt)	2016-06-28
AR082691A1 (es)	2012-12-26
KR101475167B1 (ko)	2014-12-19
SG188207A1 (en)	2013-04-30
AU2011290818B2 (en)	2015-08-27
KR20130043225A (ko)	2013-04-29
RS53959B1 (en)	2015-08-31
ZA201300967B (en)	2015-11-25
US8709419B2 (en)	2014-04-29
JP2013537544A (ja)	2013-10-03
ES2535000T3 (es)	2015-05-04

Publication	Publication Date	Title
IL251083B (en)	2018-07-31	Compounds and preparations for the treatment of cancer
IL225471B (en)	2018-04-30	Preparations for the prevention and treatment of cancer
HK1199099A1 (en)	2015-06-19	Methods and compositions for the treatment and diagnosis of cancer
EP2542081A4 (en)	2013-07-31	COMPOSITIONS FOR CANCER TREATMENT
SG10201508495VA (en)	2015-11-27	Combination treatment of cancer
EP2688594A4 (en)	2014-07-30	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
SI2605764T1 (sl)	2015-06-30	Sestavki za zdravljenje raka
EP2723924A4 (en)	2015-03-25	METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER
IL238177A0 (en)	2015-05-31	Methods and preparations for the treatment of cancer
EP2654745A4 (en)	2014-03-26	COMPOSITION FOR TREATING SKIN CONDITIONS OF THE SKIN
IL213761A0 (en)	2011-07-31	Novel ortho-aminoamides for the treatment of cancer
EP2558085A4 (en)	2013-10-09	COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER
IL222958A0 (en)	2013-02-03	Cancer treatment
IL214349A0 (en)	2011-09-27	Compositions and methods for the treatment of cancer
HK1185874A1 (zh)	2014-02-28	用於治療癌症的新的 -氨基- -羥基-苯甲酰胺
EP2608671A4 (en)	2013-08-07	COMPOUNDS USED IN THE TREATMENT OF CANCER
ZA201300762B (en)	2014-07-30	Novel combination therapy for the treatment of cancer
EP2437738A4 (en)	2012-11-14	METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP2635273A4 (en)	2014-06-11	ISOFLAVONOID COMPOSITIONS AND METHOD FOR CANCER TREATMENT
HUE047320T2 (hu)	2020-04-28	Terméketlenség kezelésére szolgáló kompozíció
EP2547368A4 (en)	2014-08-06	METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP2411031A4 (en)	2012-08-01	Methods and compositions for the treatment of cancer
PT2460509T (pt)	2018-02-13	Composição para tratamento de verrugas
GB201017356D0 (en)	2010-11-24	Combination treatment of cancer
GB201017354D0 (en)	2010-11-24	Treatment of cancer